EyePoint
Market cap $34.1M 113.8M shares (10-Q, Nov 6, 2026) × $0.300 close Nov 17, 2026
Most recent annual filing: 2026-03-05
- Workforce reduction corporate update1H 2027Workforce reduction corporate update, 1H 2027, routine
- EYPT corporate updatelate 3Q 2027EYPT corporate update, late 3Q 2027, routine
- COMO/CAPRI DME topline4Q 2027COMO/CAPRI DME topline, 4Q 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
razuprotafib
EYP-2301- Undisclosed indication
Technology platforms
Durasert E
Next-generation bioerodible intravitreal drug delivery technology designed to provide sustained release of drug for at least six months without free-floating drug particles; used as the delivery vehicle for vorolanib in DURAVYU for serious retinal diseases including wet AMD and DME.
Discontinued (1)
- DURAVYU — Wet Age-Related Macular Degeneration · missed primary endpoint of non-inferiority in Phase 3 LUCIA study; pivotal Phase 3 wet AMD trials concluded early
Capital (as filed)
- Cash
- $83.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $35.0M Sep 30, 2026
- Operating cash flow
- −$86.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $118M cash, runway late third quarter of 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-13 UPDATE: EyePoint (EYPT) - The Runway Now Ends Before the Readout 🔒 Paid
- 2026-10-20 UPDATE: EyePoint (EYPT) - Zero for Two
- 2026-09-10 UPDATE: EyePoint (EYPT) - They Ran the Analysis I Asked For 🔒 Paid
- 2026-08-17 UPDATE: EyePoint (EYPT) - LUGANO Missed. Nine Patients Broke the Thesis.
- 2026-08-06 UPDATE: EyePoint (EYPT) - The Last Quarter Before the Verdict 🔒 Paid
- 2026-07-30 UPDATE: EyePoint (EYPT) - The Binary Event Now Has a Month 🔒 Paid
- 2026-07-17 UPDATE: EyePoint (EYPT) — The DOJ Overhang Clears for Pocket Change 🔒 Paid
- 2026-05-07 UPDATE: EyePoint (EYPT) — Q1 2026 Status Check Into the LUGANO Window 🔒 Paid
- 2026-05-01 EyePoint Pharmaceuticals (EYPT) - Scientific Deep Dive for DURAVYU and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on EyePoint, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-01 Buy core EyePoint Pharmaceuticals (EYPT) - Scientific Deep Dive for DURAVYU and Pipeline Products Asymmetric binary setup ahead of mid-2026 Phase 3 LUGANO/LUCIA readouts, backed by clean Phase 2 data, multi-MOA science, and cash runway that bridges the pre-data dilution gap.
- 2026-05-07 Buy core UPDATE: EyePoint (EYPT) — Q1 2026 Status Check Into the LUGANO Window Interim masked Phase 3 safety read across 900+ patients is clean and catalyst calendar is intact, though cash burn is faster than originally modeled and manufacturing risk remains unaddressed.
- 2026-07-17 Buy core UPDATE: EyePoint (EYPT) — The DOJ Overhang Clears for Pocket Change DOJ/False Claims Act settlement resolved for ~$4.85M (a rounding error vs. cash), narrowing the bear case to just the unresolved Watertown Warning Letter ahead of imminent LUGANO topline.
- 2026-07-30 Buy core UPDATE: EyePoint (EYPT) - The Binary Event Now Has a Month LUGANO topline tightened to August 2026, DSMC continuation across 1,400+ Phase 3 patients removes the most common failure mode, and DME enrollment completed ahead of schedule; Watertown remains the sole unaddressed risk.
- 2026-08-06 Buy core UPDATE: EyePoint (EYPT) - The Last Quarter Before the Verdict Clinical thesis and August LUGANO timing unchanged, but balance sheet is thinner than originally modeled after $37.7M ATM raise and $94.5M Q2 burn, with LUCIA now pushed to Q4 2026 amplifying single-trial readout variance.
- 2026-08-17 Hold UPDATE: EyePoint (EYPT) - LUGANO Missed. Nine Patients Broke the Thesis. LUGANO missed its primary endpoint on the full dataset; asset is damaged but not dead given clean anatomic data and burden reduction, with LUCIA now the sole binary event and a financing overhang as the near-term killer.
- 2026-09-10 Hold UPDATE: EyePoint (EYPT) - They Ran the Analysis I Asked For Expanded LUGANO analyses (no 10-14 letter imbalance, GA growth matching fellow eye, baseline lesion location imbalance) strengthen the asymmetric-cohort explanation but do not change what LUCIA must do; financing overhang and Watertown remain unresolved.
- 2026-10-20 Avoid UPDATE: EyePoint (EYPT) - Zero for Two LUCIA missed non-inferiority outright with a normal control arm, wet AMD program is being shut down, the failure was efficacy not bad luck, and the remaining DME program rests on a thin Phase 2 base with a cash position unlikely to reach the Q4 2027 readout unaided.
- 2026-11-13 Avoid UPDATE: EyePoint (EYPT) - The Runway Now Ends Before the Readout Management's own cash runway now ends before the Q4 2027 DME readout, a going-concern warning has been issued, 25% dilution occurred at $0.44/share, and the only remaining catalyst is a below-even-odds binary with no non-dilutive financing yet disclosed.
- Long call · opened May 1, 2026 at $13.34 · closed Oct 20, 2026 (flipped bearish (avoid)) at $0.410 · -96.9% vs XBI +17.5%
- Avoid call · opened Oct 20, 2026 at $0.410 · -26.8% vs XBI -5.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (4 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Company remains on track to report topline data from the second wet AMD pivotal Phase 3 LUCIA trial in the fourth quarter of 2026.”
matched to DURAVYU (LUCIA trial, wet AMD) · topline data
-
-
-
“The ASU is effective for annual periods beginning after December 15, 2026, and interim periods within those annual reporting periods, with early adoption permitted.”
matched to COMO/CAPRI (DME) · topline data -
“DURAVYU is currently being evaluated in Phase 3 pivotal trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD) with initial data readout expected in August 2026.”
matched to DURAVYU (LUCIA trial, wet AMD) · topline data / matched to DURAVYU (LUGANO trial, wet AMD) · topline data
-
-
-
“DURAVYU is currently being evaluated in Phase 3 pivotal trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD) with initial data readout expected in August 2026.”
matched to DURAVYU (LUGANO trial, wet AMD) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (32)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 19, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseEyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q just delivered a going-concern qualification and confirmed that EyePoint sold nearly 23 million shares at $0.44 post-quarter — adding ~25% dilution at current prices to extend a runway that now only reaches late Q3 2027, while the stock sits below Nasdaq's $1.00 minimum-bid threshold with the delisting clock running.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 6, 2026ReleaseEyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
- Nov 5, 2026ReleaseEyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
- Oct 19, 2026ReleaseEyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD→ BD updateSummary on the 8-K
- Oct 19, 2026ReleaseEyePoint Announces Strategic Prioritization→ BD updateSummary on the 8-K
- Oct 19, 20268-KCurrent report: results of operations, exit / restructuring costs, other events · EX-99.1→ BD updateLUCIA confirmed what LUGANO started: two identical Phase 3 trials, two missed primary endpoints, and now a 53% workforce reduction and early AMD trial termination that leaves EYPT a drastically smaller company betting everything on a DME readout 14 months away with $118M in cash.BD extracted 2 program updates from this document → EYPT pipeline
- Oct 19, 20268-KCurrent report: other events · EX-99.1→ BD updateSummary on the 8-K
- Sep 10, 20268-KCurrent report: other events · EX-99.1→ BD updateEyePoint published its full LUGANO expanded analysis at the Retina Society Annual Meeting today, adding new data that directly answers several of the unanswered scientific questions from the August 17 miss — including a 10/10 randomization simulation supporting regression-to-the-mean, GA foveal proximity imbalance, and a striking fibrosis signal — strengthening the case that LUCIA remains a genuine coin flip rather than a foregone conclusion.BD extracted 1 program update from this document → EYPT pipeline
- Sep 2, 2026ReleaseEyePoint Announces Participation at Upcoming Investor Conferences and Scientific MeetingBD extracted 1 program update from this document → EYPT pipeline
- Aug 17, 2026ReleaseEyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMDBD extracted 1 program update from this document → EYPT pipeline
- Aug 17, 20268-KCurrent report: other events · EX-99.1
- Aug 5, 2026ReleaseEyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
- Aug 5, 20268-KCurrent report: results of operations · EX-99.1
- Aug 5, 202610-QQuarterly report
- Jul 30, 2026ReleaseEyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
- Jul 30, 20268-KCurrent report: other events · EX-99.1
- Jul 17, 20268-KCurrent report: material agreement
- Jul 13, 2026ReleaseEyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
- Jun 22, 20268-KCurrent report: officer / director change, shareholder vote
- May 19, 2026ReleaseEyePoint Announces Participation at Upcoming Investor Conferences
- May 14, 20268-KCurrent report: other events · EX-99.1
- May 7, 202610-QQuarterly report
- May 6, 20268-KCurrent report: results of operations · EX-99.1
- Apr 27, 2026DEFA14AProxy soliciting material
- Apr 27, 2026DEF 14AProxy statement
- Apr 13, 20268-KCurrent report: other events · EX-99.1
- Mar 20, 20268-KCurrent report: Reg FD disclosure
- Mar 5, 202610-KAnnual report
- Mar 4, 20268-KCurrent report: results of operations · EX-99.1
- Mar 2, 20268-KCurrent report: other events · EX-99.1
16 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 4, 2026SCHEDULE 13G/A13G amendment
- Oct 30, 2026SCHEDULE 13G/A13G amendment
- Oct 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Oct 7, 2026SCHEDULE 13G/A13G amendment
- Sep 8, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 12, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 5, 2026S-8Employee plan registration
- Jul 31, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 28, 2026SCHEDULE 13G/A13G amendment
- Jun 3, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026SCHEDULE 13G/A13G amendment
- Mar 26, 2026SCHEDULE 13G/A13G amendment